Nobel laureate and DeepMind CEO Demis Hassabis envisions a future where AI revolutionizes healthcare by drastically accelerating drug development—from years to weeks—and potentially curing all ...

There has been much speculation over how AI will help with healthcare, but some experts believe it can have a dramatic impact ...

London-based startups attracted £2.69bn in VC in 2025 so far, marking a robust start of the year despite a fall in deal ...

But when U.S. National Institute of Standards and Technology researchers Christina Bergonzo and Alexander Grishaev put ...

President Donald Trump’s tariffs are drawing swift retaliation from China, Canada and the European Union, deepening the ...

Isomorphic Labs is the secretive AI life science startup spun out of Google DeepMind with the goal of solving all disease ...

NVIDIA will be the first industry partner to adopt SynthID, a Google DeepMind AI technology that embeds digital watermarks directly into AI-generated images, audio, text or video.

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design and ...

Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, Isomorphic Labs.

AlphaFold’s success would pave the way for Isomorphic Labs, a spinoff focused on AI-driven drug discovery. Isomorphic was founded in 2021, but it wasn’t until yesterday that the company ...

Turns out AI can be used for more than Ghibli-ifying selfies. AI drug developer Isomorphic Labs raised $600 million in its first external funding round as hype builds around AI-powered biotech.

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup ...